Literature DB >> 19157811

A decision aid for intensity-modulated radiation-therapy plan selection in prostate cancer based on a prognostic Bayesian network and a Markov model.

Wade P Smith1, Jason Doctor, Jürgen Meyer, Ira J Kalet, Mark H Phillips.   

Abstract

OBJECTIVE: The prognosis of cancer patients treated with intensity-modulated radiation-therapy (IMRT) is inherently uncertain, depends on many decision variables, and requires that a physician balance competing objectives: maximum tumor control with minimal treatment complications.
METHODS: In order to better deal with the complex and multiple objective nature of the problem we have combined a prognostic probabilistic model with multi-attribute decision theory which incorporates patient preferences for outcomes.
RESULTS: The response to IMRT for prostate cancer was modeled. A Bayesian network was used for prognosis for each treatment plan. Prognoses included predicting local tumor control, regional spread, distant metastases, and normal tissue complications resulting from treatment. A Markov model was constructed and used to calculate a quality-adjusted life-expectancy which aids in the multi-attribute decision process.
CONCLUSIONS: Our method makes explicit the tradeoffs patients face between quality and quantity of life. This approach has advantages over current approaches because with our approach risks of health outcomes and patient preferences determine treatment decisions.

Entities:  

Mesh:

Year:  2009        PMID: 19157811      PMCID: PMC2684564          DOI: 10.1016/j.artmed.2008.12.002

Source DB:  PubMed          Journal:  Artif Intell Med        ISSN: 0933-3657            Impact factor:   5.326


  36 in total

1.  Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer.

Authors:  Andre Konski; Deborah Watkins-Bruner; Steven Feigenberg; Alexandra Hanlon; Sachin Kulkarni; J Robert Beck; Eric M Horwitz; Alan Pollack
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-08-02       Impact factor: 7.038

2.  Incidence of late rectal bleeding in high-dose conformal radiotherapy of prostate cancer using equivalent uniform dose-based and dose-volume-based normal tissue complication probability models.

Authors:  Matthias Söhn; Di Yan; Jian Liang; Elisa Meldolesi; Carlos Vargas; Markus Alber
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-01-26       Impact factor: 7.038

3.  Late gastrointestinal morbidity after three-dimensional conformal radiation therapy for prostate cancer fades with time in contrast to genitourinary morbidity.

Authors:  Asa Karlsdóttir; Ludvig Paul Muren; Tore Wentzel-Larsen; Olav Dahl
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-12-03       Impact factor: 7.038

4.  A multiplan treatment-planning framework: a paradigm shift for intensity-modulated radiotherapy.

Authors:  Robert R Meyer; Hao H Zhang; Laura Goadrich; Daryl P Nazareth; Leyuan Shi; Warren D D'Souza
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-05-23       Impact factor: 7.038

5.  Prognostic Bayesian networks I: rationale, learning procedure, and clinical use.

Authors:  Marion Verduijn; Niels Peek; Peter M J Rosseel; Evert de Jonge; Bas A J M de Mol
Journal:  J Biomed Inform       Date:  2007-07-25       Impact factor: 6.317

6.  Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial.

Authors:  Mack Roach; Michelle DeSilvio; Richard Valicenti; David Grignon; Sucha O Asbell; Colleen Lawton; Charles R Thomas; William U Shipley
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-11-01       Impact factor: 7.038

7.  Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005.

Authors:  Danil V Makarov; Bruce J Trock; Elizabeth B Humphreys; Leslie A Mangold; Patrick C Walsh; Jonathan I Epstein; Alan W Partin
Journal:  Urology       Date:  2007-06       Impact factor: 2.649

8.  Decision analysis using individual patient preferences to determine optimal treatment for localized prostate cancer.

Authors:  Benjamin D Sommers; Clair J Beard; Anthony V D'Amico; Douglas Dahl; Irving Kaplan; Jerome P Richie; Richard J Zeckhauser
Journal:  Cancer       Date:  2007-11-15       Impact factor: 6.860

9.  Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate?

Authors:  Andre Konski; William Speier; Alexandra Hanlon; J Robert Beck; Alan Pollack
Journal:  J Clin Oncol       Date:  2007-08-20       Impact factor: 44.544

10.  A comparison of the performance of microsatellite and methylation urine analysis for predicting the recurrence of urothelial cell carcinoma, and definition of a set of markers by Bayesian network analysis.

Authors:  Morgan Rouprêt; Vincent Hupertan; David R Yates; Eva Comperat; James W F Catto; Mark Meuth; Amine Lackmichi; Sylvie Ricci; Roger Lacave; Bernard Gattegno; François Richard; Freddie C Hamdy; Olivier Cussenot
Journal:  BJU Int       Date:  2008-03-04       Impact factor: 5.588

View more
  9 in total

1.  How to compare treatment plans? Personalized perspective.

Authors:  Tomasz Piotrowski; Agata Jodda
Journal:  Rep Pract Oncol Radiother       Date:  2014-07-15

Review 2.  Artificial intelligence in radiotherapy.

Authors:  Sarkar Siddique; James C L Chow
Journal:  Rep Pract Oncol Radiother       Date:  2020-05-06

Review 3.  Enhancing Career Paths for Tomorrow's Radiation Oncologists.

Authors:  Neha Vapiwala; Charles R Thomas; Surbhi Grover; Mei Ling Yap; Timur Mitin; Lawrence N Shulman; Mary K Gospodarowicz; John Longo; Daniel G Petereit; Ronald D Ennis; James A Hayman; Danielle Rodin; Jeffrey C Buchsbaum; Bhadrasain Vikram; May Abdel-Wahab; Alan H Epstein; Paul Okunieff; Joel Goldwein; Patrick Kupelian; Joanne B Weidhaas; Margaret A Tucker; John D Boice; Clifton David Fuller; Reid F Thompson; Andrew D Trister; Silvia C Formenti; Mary-Helen Barcellos-Hoff; Joshua Jones; Kavita V Dharmarajan; Anthony L Zietman; C Norman Coleman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-05-22       Impact factor: 7.038

4.  A hierarchical evolutionary algorithm for multiobjective optimization in IMRT.

Authors:  Clay Holdsworth; Minsun Kim; Jay Liao; Mark H Phillips
Journal:  Med Phys       Date:  2010-09       Impact factor: 4.071

5.  A Bayesian network approach for modeling local failure in lung cancer.

Authors:  Jung Hun Oh; Jeffrey Craft; Rawan Al Lozi; Manushka Vaidya; Yifan Meng; Joseph O Deasy; Jeffrey D Bradley; Issam El Naqa
Journal:  Phys Med Biol       Date:  2011-02-18       Impact factor: 3.609

6.  Role of positron emission tomography in the treatment of occult disease in head-and-neck cancer: a modeling approach.

Authors:  Mark H Phillips; Wade P Smith; Upendra Parvathaneni; George E Laramore
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-05-25       Impact factor: 7.038

7.  Personalized treatment planning with a model of radiation therapy outcomes for use in multiobjective optimization of IMRT plans for prostate cancer.

Authors:  Wade P Smith; Minsun Kim; Clay Holdsworth; Jay Liao; Mark H Phillips
Journal:  Radiat Oncol       Date:  2016-03-11       Impact factor: 3.481

8.  Applying Probabilistic Decision Models to Clinical Trial Design.

Authors:  Wade P Smith; Mark H Phillips
Journal:  AMIA Jt Summits Transl Sci Proc       Date:  2018-05-18

Review 9.  Big Data Analytics for Prostate Radiotherapy.

Authors:  James Coates; Luis Souhami; Issam El Naqa
Journal:  Front Oncol       Date:  2016-06-14       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.